4 analysts have this to say about neurocrine biosciences
During the last quarter, Neurocrine Biosciences NBIX observed the following analyst notes:
Over the past 3 months, 4 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $105.75 with a high of $113.00 and a low of $98.00.
Below is a summary of how these 4 analysts rated Neurocrine Biosciences over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This average price target has increased by 4.01% over the past month.
Ratings come from analysts or specialists in banking and financial systems who publish reports for specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and conversations with important insiders to make their decisions.
Some analysts will also offer forecasts for metrics such as growth estimates, earnings and revenue to provide additional insights into stocks. Investors using analyst ratings should note that such expert advice is human-sourced and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
During the last quarter, Neurocrine Biosciences NBIX observed the following analyst notes:
Over the past 3 months, 4 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $105.75 with a high of $113.00 and a low of $98.00.
Below is a summary of how these 4 analysts rated Neurocrine Biosciences over the past 3 months. The higher the number of bullish ratings, the more analysts are positive on the security and the higher the number of bearish ratings, the more analysts are negative on the security
This average price target has increased by 4.01% over the past month.
Ratings come from analysts or specialists in banking and financial systems who publish reports for specific stocks or defined sectors (usually once a quarter for each stock). Analysts typically draw their information from company conference calls and meetings, financial statements, and conversations with important insiders to make their decisions.
Some analysts will also offer forecasts for metrics such as growth estimates, earnings and revenue to provide additional insights into stocks. Investors using analyst ratings should note that such expert advice is human-sourced and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
What's Your Reaction?
